Andrew Hill Dumps 38,000 Johnson & Johnson Shares in Q2 2025 Exit

Core Insights - Andrew Hill Investment Advisors, Inc. has completely exited its position in Johnson & Johnson, selling all 38,037 shares for a total of $6.31 million during Q2 2025 [1][2][3] Company Overview - Johnson & Johnson has a market capitalization of $379 billion, with trailing twelve months (TTM) revenue of $89.3 billion and net income of $21.8 billion as of July 10, 2025 [5] - The company offers a diversified portfolio that includes pharmaceutical, medical technology, and consumer health products, with well-known brands such as TYLENOL, NEUTROGENA, LISTERINE, and ACUVUE [6][7] - Johnson & Johnson serves a wide customer base, including hospitals, healthcare professionals, retailers, and distributors globally [6] Financial Performance - As of July 10, 2025, Johnson & Johnson's stock closed at $157.69, with a 12-month return of 7.2%, trailing the S&P 500 by 5.4 percentage points [4] - The company has a dividend yield of 3.18% and a forward P/E ratio of 14.86 [4][5] - The Innovative Medicine segment accounted for 64% of total sales, with significant contributions from oncology, cardiovascular, and pulmonary hypertension products [10] Growth and Innovation - Johnson & Johnson generated $88.8 billion in sales and nearly $20 billion in free cash flow in 2024, with 26 products exceeding $1 billion in sales [10][11] - The company invested nearly $50 billion in research and development (R&D) and acquisitions in the previous year, emphasizing its commitment to innovation [11] - Johnson & Johnson is recognized as a Dividend King, having increased its dividend for 63 consecutive years, reflecting its focus on organic growth and shareholder returns [12]